Abstract: PO0591
Magnesium Supplements Reduce Arterial Stiffness in Patients with CKD Stage 3-4 but Do Not Affect Bone Mineral Density
Session Information
- Vascular Disease, Nephrolithiasis, and Mineral Metabolism: Clinical
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Pendon-Ruiz de Mier, Victoria, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Santamaria, Rafael, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Peregrin, Cayetana Moyano, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- López-López, Isabel, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Membrives González, Cristina, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Rodriguez Ortiz, Maria Encarnacion, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Gordillo Arnaud, Jose E., Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Chamizo, Asuncion Salmoral, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Munoz-Castaneda, Juan R., Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Rodelo-Haad, Cristian, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Martin-Malo, Alejandro, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Soriano Cabrera, Maria Sagrario, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
- Rodriguez, Mariano, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
Background
Chronic Kidney Disease (CKD) entails to mineral metabolism disorders and vascular calcifications (VC). In vitro and in vivo, magnesium (Mg) supplements inhibits VC and show a beneficial effect on kidney function. However, some authors have suggested that Mg could affect bone turnover. We performed a study to evaluate the effect of dietary supplementation with Mg on arterial stiffness and bone mineral density in patients with CKD stage 3-4 and VC.
Methods
Randomized, open-label, parallel-group clinical trial (control/experimental) (n=8 per group). The experimental group received 360mg of Mg carbonate daily for 15±1.5 months. At the beginning and at the end of the study, blood and urinary biomarkers of bone mineral metabolism were measured; pulse wave velocity (PWV) was determined with Mobil-O-Graph device as an indicator of arterial stiffness, the Adragao index was calculated and bone mineral density was measured by densitometry.
Results
The included patients were in both groups mostly men and similar with respect to age and GFR. Serum Mg concentration were 1.9±0.1 vs 2±0.1mg/dl in control and experimental group respectively. At the baseline, no differences were found in demographic characteristics, comorbidities, treatments, PWV or biomarkers of bone mineral metabolism. The experimental group did not present hypermagnesemia or any other adverse event. The increase in urine Mg confirmed the therapeutic adherence. There was a decrease in GFR: 4ml/min in control and 1.71ml/min in experimental group, with no changes in serum Mg (both not statistically significant). An inverse correlation was found between urine Mg and the albumin/creatinine ratio (p=0.039). At the end of follow-up, serum Mg was inversely correlated with PWV (p=0.015). Urinary Mg was inversely correlated with iFGF23 (p=0.007). A non-significant trend of decrease in the Adragao index was observed in the experimental group. There were no changes in bone mineral density.
Conclusion
In CKD3-4 patients the Mg supplements reduce arterial stiffness without changes in bone mineral density.